Stay updated on Ipilimumab/Nivolumab in High-Risk Ocular Melanoma Clinical Trial

Sign up to get notified when there's something new on the Ipilimumab/Nivolumab in High-Risk Ocular Melanoma Clinical Trial page.
Latest website image capture
Clouds background image

Latest updates to the Ipilimumab/Nivolumab in High-Risk Ocular Melanoma Clinical Trial page

  1. Check
    2 days ago
    No Change Detected
  2. Check
    10 days ago
    No Change Detected
  3. Check
    17 days ago
    No Change Detected
  4. Check
    24 days ago
    Change Detected
    Summary
    Revision added: v3.5.0; revision v3.4.3 removed.
    Difference
    0.1%
    Check dated 2026-03-18T19:52:14.000Z thumbnail image
  5. Check
    31 days ago
    Change Detected
    Summary
    Revision updated from v3.4.2 to v3.4.3. This appears to be an internal version update with no changes to study content or eligibility.
    Difference
    0.1%
    Check dated 2026-03-11T17:57:20.000Z thumbnail image
  6. Check
    59 days ago
    Change Detected
    Summary
    Revision: v3.4.2 has been added to the page. The prior government funding/operating status notice (v3.4.1) has been removed.
    Difference
    0.4%
    Check dated 2026-02-11T09:59:57.000Z thumbnail image
  7. Check
    66 days ago
    Change Detected
    Summary
    Added a site-wide funding-status notice about a lapse in government funding with references to cc.nih.gov and opm.gov. Updated the page revision from v3.4.0 to v3.4.1.
    Difference
    0.4%
    Check dated 2026-02-04T06:55:46.000Z thumbnail image
  8. Check
    74 days ago
    Change Detected
    Summary
    Added a Show glossary option; introduced the 'Revision: v3.4.0' label and standardized the QC update label to 'Last Update Submitted that Met QC Criteria'. Standardized capitalization for FEAR Act-related text across the page.
    Difference
    0.2%
    Check dated 2026-01-28T05:45:51.000Z thumbnail image
  9. Check
    88 days ago
    Change Detected
    Summary
    Footer revision updated from v3.3.3 to v3.3.4. No study details, eligibility criteria, or results are changed.
    Difference
    0.1%
    Check dated 2026-01-14T03:12:48.000Z thumbnail image

Stay in the know with updates to Ipilimumab/Nivolumab in High-Risk Ocular Melanoma Clinical Trial

Enter your email address, and we'll notify you when there's something new on the Ipilimumab/Nivolumab in High-Risk Ocular Melanoma Clinical Trial page.